Verso M, Agnelli G, Prandoni P (2015) Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. Intern Emerg Med 10:651–656. https://doi.org/10.1007/s11739-015-1233-5

Article  PubMed  Google Scholar 

Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS (2000) Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 160:3431–3436. https://doi.org/10.1001/archinte.160.22.3431

Article  CAS  PubMed  Google Scholar 

Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18:3078–3083. https://doi.org/10.1200/jco.2000.18.17.3078

Article  CAS  PubMed  Google Scholar 

Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D’Angelo A, Pengo V, Moia M, Coccheri S (2000) A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 84:805–810. https://doi.org/10.1055/s-0037-1614120

Article  CAS  PubMed  Google Scholar 

Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488. https://doi.org/10.1182/blood-2002-01-0108

Article  CAS  PubMed  Google Scholar 

Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153. https://doi.org/10.1056/NEJMoa025313

Article  CAS  PubMed  Google Scholar 

Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A (2023) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 41:3063–3071. https://doi.org/10.1200/jco.23.00294

Article  CAS  PubMed  Google Scholar 

Streiff MB, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R et al (2025) Cancer-Associated Venous Thromboembolic Disease, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf. Accessed 15 Oct 2025

Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies (2004) Lancet 363:157–163. https://doi.org/10.1016/S0140-6736(0)15268-3

Ten Cate H (2013) New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J 11:8. https://doi.org/10.1186/1477-9560-11-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2016) Use of the direct oral anticoagulants in obese patients: guidance from the ssc of the ISTH. J Thromb Haemost 14:1308–1313. https://doi.org/10.1111/jth.13323

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2021) Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH ssc subcommittee on control of anticoagulation. J Thromb Haemost 19:1874–1882. https://doi.org/10.1111/jth.15358

Article  PubMed  Google Scholar 

Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119–2126. https://doi.org/10.1111/jth.13140

Article  CAS  PubMed  Google Scholar 

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381. https://doi.org/10.1016/j.jbi.2008.08.010

Article  PubMed  Google Scholar 

McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 18:411–421. https://doi.org/10.1111/jth.14662

Article  CAS  PubMed  Google Scholar 

Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382:1599–1607. https://doi.org/10.1056/NEJMoa1915103

Article  CAS  PubMed  Google Scholar 

Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M (2018) Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol 36:2017–2023. https://doi.org/10.1200/jco.2018.78.8034

Article  CAS  PubMed  Google Scholar 

Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 43:1064–1083. https://doi.org/10.1345/aph.1L194

Article  CAS  PubMed  Google Scholar 

Sebaaly J, Covert K (2018) Enoxaparin dosing at extremes of weight: literature review and dosing recommendations. Ann Pharmacother 52:898–909. https://doi.org/10.1177/1060028018768449

Article  CAS  PubMed  Google Scholar 

Abildgaard A, Madsen SA, Hvas AM (2020) Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin Thromb Hemost 46:932–969. https://doi.org/10.1055/s-0040-1718405

Article  PubMed  Google Scholar 

Wysokinski WE, Froehling DA, Houghton DE, McBane RD, Vlazny DT, Bott-Kitslaar DM, Kuczmik W, Sutkowska K, Bator K, Hodge DO, Peterson LG, Casanegra AI (2020) Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight. Eur J Haematol 105:484–494. https://doi.org/10.1111/ejh.13471

Article  CAS  PubMed  Google Scholar 

Karakasis P, Ktenopoulos N, Pamporis K, Sagris M, Soulaidopoulos S, Gerogianni M, Leontsinis I, Giannakoulas G, Tousoulis D, Fragakis N, Tsioufis K (2024) Efficacy and safety of direct oral anticoagulants versus warfarin in obese patients (BMI ≥ 30 kg/m(2)) with atrial fibrillation or venous thromboembolism: an updated systematic review and meta-analysis. J Clin Med 13:3784. https://doi.org/10.3390/jcm13133784

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang TF, Carrier M, Fournier K, Siegal DM, Le Gal G, Delluc A (2022) Oral anticoagulant use in patients with morbid obesity: a systematic review and meta-analysis. Thromb Haemost 122:830–841. https://doi.org/10.1055/a-1588-9155

Article  PubMed  Google Scholar 

Park DY, An S, Arif AW, Sana MK, Vij A (2023) Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. BMC Cardiovasc Disord 23:100. https://doi.org/10.1186/s12872-023-03067-4

Article  PubMed  PubMed Central  Google Scholar 

Sebaaly J, Kelley D (2020) Direct oral anticoagulants in obesity: an updated literature review. Ann Pharmacother 54:1144–1158. https://doi.org/10.1177/1060028020923584

Article  PubMed  Google Scholar 

Potere N, Di Nisio M, Porreca E, Wang TF, Tagalakis V, Shivakumar S, Delluc A, Mallick R, Wells PS, Carrier M (2023) Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: insights from the AVERT trial. Thromb Res 226:82–85. https://doi.org/10.1016/j.thromres.2023.04.015

Article  CAS  PubMed  Google Scholar 

Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol 47:218–226. https://doi.org/10.1177/0091270006296058

Article  CAS  PubMed  Google Scholar 

Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, LaCreta FP, Frost CE (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 76:908–916. https://doi.org/10.1111/bcp.12114